Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/07/071196
CTRI/2024/07/071196
Not Yet Recruiting
Phase 4

Comparison of Effectiveness and Safety of Dapagliflozin and Empagliflozin in Type 2 Diabetes Mellitus - NI

Dr Manu Arya0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr Manu Arya
Status
Not Yet Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Dr Manu Arya

Eligibility Criteria

Inclusion Criteria

  • •All Patients with Type2 diabetes mellitus as per ADA guidelines
  • •Patients of either gender with age more than 18 years.
  • •Patients giving written informed consent.

Exclusion Criteria

  • •Pregnant \& lactating women.
  • •Patients not complying with the study protocol.
  • •Patients with underlying comorbid conditions like recurrent UTI, chronic renal diseases.
  • •Patients with co\-morbid conditions like malignancy, psychiatric disorders, substance abuse
  • •Patients with concomitant medications likely to interfere with glycemic control e.g.: Steroids, Beta\-blockers, Thiazide Diuretics

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
Comparing Dapagliflozin and Glimepiride in treating patients with type 2 Diabetes.
IRCT20220408054450N1Bahria University Medical & Dental College200
Completed
N/A
Evaluation of efficiency and safety of dapagliflozin in treating of type 2 diabetes mellitustype 2 diabetes
JPRN-UMIN000023681Juntendo University Urayasu Hospital30
Active, Not Recruiting
N/A
Comparison of efficacy and safety of different regimens of sublingual immunotherapy for Ragweed.
EUCTR2011-001682-41-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)45
Recruiting
N/A
Comparison of the the Efficacy and Safety of durable polymer Novolimus-eluting Elixir DESyne X2™ Stent with Bioresorbable Polymer Sirolimus-Eluting Orsiro™ Stent in a Real World” patient populatio
KCT0005690Koera University Guro Hospital1,176
Completed
Phase 4
Comparison of efficacy and safety of Drotaverine Versus Mebeverine in Irritable Bowel Syndrome
CTRI/2017/11/010529Walter Bushnell Pvt Ltd200